Iktos Announces Collaboration With Pfizer in AI for Drug Design Iktos announced today the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs. Over the last few years, phenomenal advances in AI algorithmic development and computational power have enabled innovative approaches in small-molecule drug design. Iktos has been at the forefront of these efforts putting its generative modeling technology at work in several collaborations with pharmaceutical and biotechnology companies. A key aspect of the technology is that exploration of chemical space is performed by generating compounds in silico under the constraints of program endpoints, rather than screening libraries of compounds.